Xeris Pharmaceuticals Inc. (XERS) Reports In-Line Q1 EPS, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Xeris Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Updates
May 7, 2020 7:00 AM EDTGvoke Pre-Filled Syringe (PFS) net sales of $1.7 million in Q1 2020
Gvoke HypoPen on track for planned launch in July 2020
Initiated programs to ensure easier patient access to GVOKE in the midst of the COVID-19 pandemic
Corporate actions taken to conserve cash
Conference call and webcast today at 8:30 a.m. ET
CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU)... More
